An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors

Trial Profile

An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2016

At a glance

  • Drugs Veliparib (Primary) ; Carboplatin; Fluorouracil; Folinic acid; Irinotecan; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors AbbVie
  • Most Recent Events

    • 26 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 04 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Nov 2016.
    • 04 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top